Get the Stockscreener App
6.6597
2.64%
-0.1803
Biocryst Pharmaceuticals Inc stock is traded at $6.6597, with a volume of 577.23K.
It is down -2.64% in the last 24 hours and down -6.08% over the past month.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
See More
Previous Close:
$6.84
Open:
$6.82
24h Volume:
577.23K
Relative Volume:
0.14
Market Cap:
$1.66B
Revenue:
$557.51M
Net Income/Loss:
$-35.71M
P/E Ratio:
-37.00
EPS:
-0.18
Net Cash Flow:
$15.50M
1W Performance:
+6.72%
1M Performance:
-6.08%
6M Performance:
-20.25%
1Y Performance:
-24.15%
1-Day Range:
$6.61
$6.86
1-Week Range:
$6.26
$6.905
52-Week Range:
$6.00
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Name
Biocryst Pharmaceuticals Inc
Sector
Phone
919-859-1302
Address
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
6.675 | 1.70B | 557.51M | -35.71M | 15.50M | -0.18 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.35 | 57.75B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
131.25 | 56.70B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.19 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.92 | 39.96B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
473.07 | 20.49B | 3.13B | 1.27B | 1.12B | 26.39 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-25 | Resumed | TD Cowen | Buy |
| Oct-01-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-25 | Initiated | Wedbush | Outperform |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Sep-18-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-04-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-13-23 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-22-23 | Upgrade | Needham | Hold → Buy |
| Nov-02-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-05-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-05-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-18-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Aug-06-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-03-21 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Sep-29-20 | Resumed | JP Morgan | Overweight |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| May-05-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-15-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| May-24-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-16-18 | Resumed | Piper Jaffray | Overweight |
| Aug-08-18 | Resumed | JP Morgan | Overweight |
| Jul-17-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jun-22-18 | Initiated | Seaport Global Securities | Neutral |
| Jan-02-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-20-17 | Initiated | Barclays | Equal Weight |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-06-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-17 | Upgrade | Jefferies | Hold → Buy |
| Feb-16-17 | Initiated | Ladenburg Thalmann | Buy |
| Aug-12-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-04-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | FBR Capital | Outperform |
| Feb-09-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-09-16 | Downgrade | Needham | Buy → Hold |
View All
Biocryst Pharmaceuticals Inc Stock (BCRX) Latest News
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting - The Manila Times
BioCryst Pharmaceuticals to Present Nine Abstracts on Hereditary Angioedema at 2026 AAAAI Annual Meeting - Quiver Quantitative
Shots every 3–6 months suppress HAE attacks in BioCryst trial data - Stock Titan
BioCryst to Present New HAE Data from ORLADEYO® - GlobeNewswire
What catalysts could drive BioCryst Pharmaceuticals Inc. stock higherMarket Performance Summary & Low Risk Profit Maximizing Plans - mfd.ru
Why BioCryst Pharmaceuticals Inc. stock is a must watch in 2025Earnings Miss & Weekly High Potential Stock Alerts - mfd.ru
BioCryst Acquisition Of Astria Highlights Rare Disease Focus And Valuation Gap - Yahoo Finance
Jim Cramer on BioCryst Pharmaceuticals: "Just Stay Away From That" - Finviz
BioCryst Uses Equity Grants To Support Rare Disease Pipeline And Talent - Sahm
Jim Cramer on BioCryst Pharmaceuticals: “Just Stay Away From That” - Insider Monkey
(BCRX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Jim Cramer Commented on These 14 Stocks - Insider Monkey
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 - The Globe and Mail
ADARx Pharmaceuticals Appoints Donald Fong as CMO - Contract Pharma
BioCryst (BCRX) Grants Stock Options and RSUs to New Employees - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 | Nation/World | bdtonline.com - Bluefield Daily Telegraph
Will BioCryst's ORLADEYO Hit The $1 Billion Sales Mark? - RTTNews
BioCryst Pharmaceuticals, Inc. (BCRX) Investor Outlook: Exploring a Potential 226.80% Upside - DirectorsTalk Interviews
Biocryst expands HAE treatment portfolio with Astria acquisition - Angioedema News
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Analysts Offer Insights on Healthcare Companies: Steris (STE), Arcellx Inc (ACLX) and BioCryst (BCRX) - The Globe and Mail
BioCryst Pharmaceuticals Is Quietly Exploding – Is BCRX the Next Sleeper Biotech Rocket or a Total - AD HOC NEWS
BCRX: Analyst Maintains Rating but Lowers Price Target to $13 | - GuruFocus
Royal Bank Of Canada Lowers BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $13.00 - MarketBeat
RBC Cuts Price Target on BioCryst Pharmaceuticals to $13 From $14, Keeps Outperform Rating - marketscreener.com
Is BioCryst Pharmaceuticals Inc. backed by strong institutional buyingRate Hike & AI Powered Buy/Sell Recommendations - Mfd.ru
Does Blackstone’s US$400 Million Deal and Astria Hires Change The Bull Case For BioCryst (BCRX)? - Sahm
Is BioCryst Pharmaceuticals Inc.’s growth already priced inJuly 2025 Final Week & AI Optimized Trade Strategies - mfd.ru
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: A 198% Potential Upside for Investors - DirectorsTalk Interviews
(BCRX) Risk Channels and Responsive Allocation - Stock Traders Daily
Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Pressure And Rare Disease Pipeline Focus - Yahoo Finance
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema - Sahm
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Mixed Recent Share Price Performance - Sahm
Astria Therapeutics Completes Merger and Goes Private - TipRanks
BioCryst Closes Blackstone Loan and Astria Acquisition - TipRanks
BioCryst Pharmaceuticals Signs Loan Agreement With Blackstone and Lenders - TradingView
Astria Therapeutics Signs Loan Agreement Joinder With BioCryst Pharmaceuticals - TradingView
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 5.3%Still a Buy? - MarketBeat
BioCryst Completes Acquisition of Astria Therapeutics (ATXS) - GuruFocus
BioCryst completes $700 million acquisition of Astria Therapeutics - Investing.com
BioCryst Pharmaceuticals Completes Acquisition of Astria Therapeutics to Enhance HAE Portfolio - Quiver Quantitative
Hereditary Angioedema Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
BioCryst Pharmaceuticals, Inc. announced that it expects to receive $400 million in funding - marketscreener.com
BioCryst: The $700 Million Pivot From Oral Convenience To Injectable - Seeking Alpha
Clearside Biomedical Shares Surge Amid Bankruptcy Proceedings - AD HOC NEWS
Astria stockholders approve acquisition by BioCryst - Investing.com Australia
Astria stockholders approve acquisition by BioCryst By Investing.com - Investing.com South Africa
Astria Stockholders Vote to Approve Acquisition by BioCryst - citybiz
Astria stockholders vote to approve acquisition by BioCryst - marketscreener.com
Astria Therapeutics (ATXS) Stockholders Approve BioCryst Merger - GuruFocus
Biocryst Pharmaceuticals Inc Stock (BCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
8.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):